Naftazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Naftazone is a naphthoquinone derivative indicated in the treatment of varicose veins, hemorrhoids, and superficial thrombophlebitis.

Generic Name
Naftazone
DrugBank Accession Number
DB13680
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 215.212
Monoisotopic: 215.069476542
Chemical Formula
C11H9N3O2
Synonyms
  • Naftazona
  • Naftazone
  • Naftazonum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofChronic venous insufficiency (cvi)••••••••••••••••••
Treatment ofHemorrhoids••••••••••••••••••
Treatment ofSuperficial thrombophlebitis••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with or without food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Mediaven / Mediavene

Categories

ATC Codes
C05CX02 — Naftazone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Aryl ketones / Semicarbazones / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic homopolycyclic compound / Aryl ketone / Carbonyl group / Hydrocarbon derivative / Ketone / Naphthalene / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
15B0523P5L
CAS number
15687-37-3
InChI Key
TZGBBMBARSFJBG-UKTHLTGXSA-N
InChI
InChI=1S/C11H9N3O2/c12-11(16)14-13-9-6-5-7-3-1-2-4-8(7)10(9)15/h1-6H,(H3,12,14,16)/b13-9+
IUPAC Name
{[(2E)-1-oxo-1,2-dihydronaphthalen-2-ylidene]amino}urea
SMILES
NC(=O)N\N=C1/C=CC2=CC=CC=C2C1=O

References

General References
  1. TITCK Product Information: Mediaven (naftazone) oral tablets [Link]
ChemSpider
4698034
RxNav
31475
ChEBI
134890
ChEMBL
CHEMBL2106794
ZINC
ZINC000018163569

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral10 mg
TabletOral30 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.31 mg/mLALOGPS
logP1.2ALOGPS
logP1.3Chemaxon
logS-2.8ALOGPS
pKa (Strongest Acidic)11.64Chemaxon
pKa (Strongest Basic)-1.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area84.55 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity59.76 m3·mol-1Chemaxon
Polarizability21.2 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-014l-1900000000-29d0babc3af4e9abbc2b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014l-4090000000-9465057679fe1413a8bb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-0900000000-3d1db2f15ba1ea14c32b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ke-6940000000-8853e288c7ad9bf27ea2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0900000000-5828c962712c670b5536
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kf-2900000000-e46b5278345d2af0a0e5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-5fd98534e26d519275a5
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-141.59929
predicted
DeepCCS 1.0 (2019)
[M+H]+143.99486
predicted
DeepCCS 1.0 (2019)
[M+Na]+149.98949
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12